Incyte today announced new data from the Phase 3b TRuE-AD4 study evaluating the efficacy and safety of Opzelura® (ruxolitinib cream) in adults with moderate atopic dermatitis (AD) who had an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback